The Role of Natural Anticoagulants in the Pathogenesis and Management of Systemic Activation of Coagulation and Inflammation in Critically Ill Patients

ABSTRACT

Critically ill patients often have systemic activation of both inflammatory systems and coagulation. Increasing evidence points to an extensive cross-talk between these two systems, whereby inflammation leads to activation of coagulation and coagulation considerably affects inflammatory activity. The intricate relationship between inflammation and coagulation may have major consequences for the pathogenesis of microvascular failure and subsequent multiple organ failure, as a result of severe infection and the associated systemic inflammatory response. Molecular pathways that contribute to inflammation-induced activation of coagulation have been precisely identified. Activation of the coagulation system and ensuing thrombin generation is dependent on an interleukin-6–induced expression of tissue factor on activated mononuclear cells and endothelial cells and is insufficiently counteracted by tissue factor pathway inhibitor. Simultaneously, endothelial-bound anticoagulant mechanisms, in particular the protein C system and the antithrombin system, are shut off by proinflammatory cytokines. Modulation of inflammatory activity by activation of coagulation also occurs by various mechanisms. Activated coagulation proteases, such as the tissue factor–factor VIIa complex, factor Xa, and thrombin, can bind to protease-activated receptors on various cells, and the ensuing intracellular signaling leads to increased production of proinflammatory cytokines and chemokines. Activated protein C can bind to the protein C receptor on endothelial cells and mononuclear cells, thereby affecting NF-κB nuclear translocation and subsequently influencing inflammatory gene expression and inhibition of tissue factor expression on mononuclear cells. Observations in experimental models of targeted disruption of the protein C gene and restoration of the downregulated protein C pathway by administration of recombinant activated protein C support this notion.

KEYWORDS

Coagulation - inflammation - antithrombin - activated protein C - tissue factor pathway inhibitor - natural anticoagulants

REFERENCES

• 1 Opal S M, Esmon C T. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis.  Crit Care. 2003;  7 23-38
• 2 Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.  Nat Med. 2002;  8 1257-1262
• 3 van der Poll T, Levi M, Hack C E et al.. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.  J Exp Med. 1994;  179 1253-1259
• 4 van Deventer S J, Buller H R, ten Cate J W et al.. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways.  Blood. 1990;  76 2520-2526
• 5 Levi M, van der Poll T. Two-way interactions between inflammation and coagulation.  Trends Cardiovasc Med. 2005;  15 254-259
• 6 Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis.  Semin Thromb Hemost. 2006;  32 5-10
• 7 Levi M, ten Cate H, Bauer K A et al.. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.  J Clin Invest. 1994;  93 114-120
• 8 Pixley R A, De L C, Page J D et al.. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.  J Clin Invest. 1993;  91 61-68
• 9 Laterre P F, Wittebole X, Collienne C. Pharmacological inhibition of tissue factor.  Semin Thromb Hemost. 2006;  32 71-76
• 10 Osterud B, Bjorklid E. Sources of tissue factor.  Semin Thromb Hemost. 2006;  32 11-23
• 11 Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles.  Blood Coagul Fibrinolysis. 1998;  9(Suppl 1) S9-S14
• 12 Neumann F J, Marx N, Gawaz M et al.. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets.  Circulation. 1997;  95 2387-2394
• 13 Camerer E, Kolsto A B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation.  Thromb Res. 1996;  81 1-41
• 14 Edgington T S, Mackman N, Fan S T, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock.  Nouv Rev Fr Hematol. 1992;  34(Suppl) S15-S27
• 15 Giesen P L, Rauch U, Bohrmann B et al.. Blood-borne tissue factor: another view of thrombosis.  Proc Natl Acad Sci U S A. 1999;  96 2311-2315
• 16 Osterud B, Rao L V, Olsen J O. Induction of tissue factor expression in whole blood - lack of evidence for the presence of tissue factor expression on granulocytes.  Thromb Haemost. 2000;  83 861-867
• 17 Nieuwland R, Berckmans R J, McGregor S et al.. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis.  Blood. 2000;  95 930-935
• 18 Koyama T, Nishida K, Ohdama S et al.. Determination of plasma tissue factor antigen and its clinical significance.  Br J Haematol. 1994;  87 343-347
• 19 Gando S. Tissue factor in trauma and organ dysfunction.  Semin Thromb Hemost. 2006;  32 48-53
• 20 Levi M. Disseminated intravascular coagulation.  Crit Care Med. 2007;  35 2191-2195
• 21 Franco R F, de Jonge E, Dekkers P E et al.. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation.  Blood. 2000;  96 554-559
• 22 Zimmerman G A, McIntyre T M, Prescott S M, Stafforini D M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis.  Crit Care Med. 2002;  30 S294-S301
• 23 Shebuski R J, Kilgore K S. Role of inflammatory mediators in thrombogenesis.  J Pharmacol Exp Ther. 2002;  300 729-735
• 24 Levi M, van der Poll T, Buller H R. Bidirectional relation between inflammation and coagulation.  Circulation. 2004;  109 2698-2704
• 25 Levi M. Antithrombin in sepsis revisited.  Crit Care. 2005;  9 624-625
• 26 Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells.  J Cell Physiol. 1990;  144 383-390
• 27 Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action.  Crit Care. 2007;  11(Suppl 5) S3
• 28 Esmon C T. Role of coagulation inhibitors in inflammation.  Thromb Haemost. 2001;  86(1) 51-56
• 29 Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.  Crit Care Med. 2001;  29 S90-S94
• 30 Esmon C T. The regulation of natural anticoagulant pathways.  Science. 1987;  235 1348-1352
• 31 Esmon C T. The endothelial cell protein C receptor.  Thromb Haemost. 2000;  83 639-643
• 32 Perez-Casal M, Downey C, Fukudome K, Marx G, Toh C H. Activated protein C induces the release of microparticle-associated endothelial protein C receptor.  Blood. 2005;  105 1515-1522
• 33 Mesters R M, Helterbrand J, Utterback B G et al.. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications.  Crit Care Med. 2000;  28 2209-2216
• 34 Vary T C, Kimball S R. Regulation of hepatic protein synthesis in chronic inflammation and sepsis.  Am J Physiol. 1992;  262 C445-C452
• 35 Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase.  Biol Chem Hoppe Seyler. 1991;  372 1007-1013
• 36 Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor.  J Exp Med. 1986;  163 740-745
• 37 Faust S N, Levin M, Harrison O B et al.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis.  N Engl J Med. 2001;  345 408-416
• 38 Garcia de Frutos P, Alim R I, Hardig Y, Zoller B, Dahlback B. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S.  Blood. 1994;  84 815-822
• 39 Taylor F BJ, Dahlback B, Chang A C et al.. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli.  Blood. 1995;  86 2642-2652
• 40 Taylor F BJ, Stearns-Kurosawa D J, Kurosawa S et al.. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis.  Blood. 2000;  95 1680-1686
• 41 De Pont A C, Bakhtiari K, Hutten B A et al.. Endotoxaemia induces resistance to activated protein C in healthy humans.  Br J Haematol. 2006;  134 213-219
• 42 de Jonge E, Dekkers P E, Creasey A A et al.. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activtion without influencing the fibrinolytic and cytokine response during human endotoxemia.  Blood. 2000;  95 1124-1129
• 43 Creasey A A, Chang A C, Feigen L et al.. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.  J Clin Invest. 1993;  91 2850-2856
• 44 Mileno M D, Margolis N H, Clark B D et al.. Coagulation of whole blood stimulates interleukin-1 beta gene expression.  J Infect Dis. 1995;  172 308-311
• 45 van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation.  Semin Thromb Hemost. 2001;  27 639-651
• 46 de Jonge E, Friederich P W, Levi M, van der Poll T. Activation of coagulation by administration of recombinant factor VIIa elcicits interleukin-6 and interleukin-8 release in healthy humen subjects.  Clin Diagn Lab Immunol. 2003;  10 495-497
• 47 Coughlin S R. Thrombin signalling and protease-activated receptors.  Nature. 2000;  407 258-264
• 48 Roemisch J, Gray E, Hoffmann J N, Wiedermann C J. Antithrombin: a new look at the actions of a serine protease inhibitor.  Blood Coagul Fibrinolysis. 2002;  13 657-670
• 49 Opal S M. Interactions between coagulation and inflammation.  Scand J Infect Dis. 2003;  35 545-554
• 50 Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin.  Blood. 1999;  93 157-164
• 51 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells.  Thromb Res. 1990;  59 895-904
• 52 Mizutani A, Okajima K, Uchiba M et al.. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production.  Blood. 2003;  101 3029-3036
• 53 Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats.  Thromb Res. 1998;  89 233-241
• 54 Esmon C T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins.  J Exp Med. 2002;  196 561-564
• 55 Okajima K. Regulation of inflammatory responses by natural anticoagulants.  Immunol Rev. 2001;  184 258-274
• 56 Taylor F BJ, Chang A, Esmon C T et al.. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.  J Clin Invest. 1987;  79 918-925
• 57 Murakami K, Okajima K, Uchiba M et al.. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.  Blood. 1996;  87 642-647
• 58 Hancock W W, Tsuchida A, Hau H, Thomson N M, Salem H H. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to biology and therapy.  Transplant Proc. 1992;  24 2302-2303
• 59 Hancock W W, Grey S T, Hau L et al.. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses.  Transplantation. 1995;  60 1525-1532
• 60 White B, Schmidt M, Murphy C et al.. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.  Br J Haematol. 2000;  110 130-134
• 61 Levi M, Dorffler-Melly J, Reitsma P H et al.. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice.  Blood. 2003;  101 4823-4827
• 62 Lay A J, Donahue D, Tsai M J, Castellino F J. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency.  Blood. 2007;  109 1984-1991
• 63 Riewald M, Petrovan R J, Donner A, Mueller B M, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway.  Science. 2002;  296 1880-1882
• 64 Ludeman M J, Kataoka H, Srinivasan Y et al.. PAR1 cleavage and signaling in response to activated protein C and thrombin.  J Biol Chem. 2005;  280 13122-13128
• 65 Xu J, Qu D, Esmon N L, Esmon C T. Metalloproteolytic release of endothelial cell protein C receptor.  J Biol Chem. 2000;  275 6038-6044
• 66 Kurosawa S, Esmon C T, Stearns-Kurosawa D J. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18.  J Immunol. 2000;  165 4697-4703
• 67 Oganesyan V, Oganesyan N, Terzyan S et al.. The crystal structure of the endothelial protein C receptor and a bound phospholipid.  J Biol Chem. 2002;  277 24851-24854
• 68 Feistritzer C, Sturn D H, Kaneider N C, Djanani A, Wiedermann C J. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C.  J Allergy Clin Immunol. 2003;  112 375-381
• 69 Sturn D H, Kaneider N C, Feistritzer C et al.. Expression and function of the endothelial protein C receptor in human neutrophils.  Blood. 2003;  102 1499-1505
• 70 Hoffmann J N, Vollmar B, Laschke M W et al.. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.  Crit Care Med. 2004;  32 1011-1017
• 71 Nick J A, Coldren C D, Geraci M W et al.. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis.  Blood. 2004;  104 3878-3885
• 72 Shimizu S, Gabazza E C, Taguchi O et al.. Activated protein C inhibits the expression of platelet-derived growth factor in the lung.  Am J Respir Crit Care Med. 2003;  167 1416-1426
• 73 Zeng W, Matter W F, Yan S B et al.. Effect of drotrecogin alfa on human endothelial cell permeability and Rho kinase signaling.  Crit Care Med. 2004;  32 S302-S308
• 74 Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.  Blood. 2005;  105 3178-3184
• 75 Finigan J H, Dudek S M, Singleton P A et al.. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.  J Biol Chem. 2005;  280 17286-17293
• 76 Cheng T, Liu D, Griffin J H et al.. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.  Nat Med. 2003;  9 333-342
• 77 Mosnier L O, Griffin J H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor.  Biochem J. 2003;  373 65-70
• 78 Mosnier L O, Zlokovic B V, Griffin J H. The cytoprotective protein C pathway.  Blood. 2007;  109 3161-3172
• 79 Erlich J H, Boyle E M, Labriola J et al.. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation.  Am J Pathol. 2000;  157 1849-1862
• 80 Abraham E, Reinhart K, Svoboda P et al.. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind study.  Crit Care Med. 2001;  29 2081-2089
• 81 Zoldhelyi P, Chen Z Q, Shelat H S, McNatt J M, Willerson J T. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries.  Proc Natl Acad Sci U S A. 2001;  98 4078-4083
• 82 Abraham E, Reinhart K, Opal S et al.. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.  JAMA. 2003;  290 238-247
• 83 Levi M, ten Cate H, van der Poll T. Disseminated intravascular coagulation: state of the art.  Thromb Haemost. 1999;  82 695-705
• 84 Warren B L, Eid A, Singer P et al.. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 1869-1878
• 85 Kienast J, Juers M, Wiedermann C J et al.. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.  J Thromb Haemost. 2006;  4 90-97
• 86 Taylor F BJ, Toh C H, Hoots W K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86 1327-1330
• 87 Taylor F BJ, Chang A, Esmon C T et al.. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.  J Clin Invest. 1987;  79 918-925
• 88 Isobe H, Okajima K, Uchiba M et al.. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide.  Circulation. 2001;  104 1171-1175
• 89 De Backer D, Verdant C, Chierego M et al.. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis.  Crit Care Med. 2006;  34 1918-1924
• 90 Gruber A, Harker L A, Hanson S R, Kelly A B, Griffin J H. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.  Circulation. 1991;  84 2454-2462
• 91 Gruber A, Marzec U M, Bush L et al.. Relative antithrombotic and antihemostatic effects of protein C activator versus low molecular weight heparin in primates.  Blood. 2007;  109 3733-3740
• 92 Bernard G R, Ely E W, Wright T J et al.. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.  Crit Care Med. 2001;  29 2051-2059
• 93 Bernard G R, Vincent J L, Laterre P F et al.. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 94 De Pont A C, Bakhtiari K, Hutten B A et al.. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis—a case control study.  Crit Care. 2005;  9 R490-R497
• 95 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.  J Thromb Haemost. 2004;  2 1924-1933
• 96 Ely E W, Laterre P F, Angus D C et al.. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.  Crit Care Med. 2003;  31 12-19
• 97 Levi M, Levy M, Williams M D et al.. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).  Am J Respir Crit Care Med. 2007;  176 483-490
• 98 Dhainaut J F, Shorr A F, Macias W L et al.. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure.  Crit Care Med. 2005;  33 341-348
• 99 van der Poll T, Levi M, Nick J A, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans.  Am J Respir Crit Care Med. 2005;  171 1125-1128
• 100 Wang L, Bastarache J A, Wickersham N et al.. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation.  Am J Respir Cell Mol Biol. 2007;  36 497-503